Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1Phase 1 1

Status

Completed 4Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Dermatologic 1CNS 1Breast 1

Conditions

Multiple Sclerosis 2Skin Neoplasms 1Multiple Sclerosis, Relapsing-Remitting 1Melanoma 1Lymphopenia 1Glioblastoma 1Carcinoma, Basal Cell 1Breast Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Fingolimod Hydrochloride × Clear all
NCT06705608 2024-11-26

MS; FTY720

University of British Columbia

Completed
4,000 enrolled
Dermatologic

Carcinoma, Basal Cell, Melanoma, Multiple Sclerosis, Skin Neoplasms, Multiple Sclerosis, Relapsing-Remitting

NCT03941743 2023-07-21

Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer

Mayo Clinic

Phase 1 Completed
2 enrolled
Breast

Breast Neoplasms

NCT02939079 2019-05-14

Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients

Isfahan University of Medical Sciences

Phase 2/3 Completed
50 enrolled 20 charts

Multiple Sclerosis

NCT02490930 2017-09-13

A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Completed
5 enrolled
CNS

Astrocytoma, Glioblastoma, Lymphopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡